Perrigo Company has received final approval for its abbreviated new drug application for fluticasone propionate lotion, 0.05 per cent, the generic equivalent to Cutivate Lotion, 0.05 per cent. Perrigo will commence shipment of the product immediately.
Cutivate Lotion 0.05 per cent (fluticasone propionate lotion, 0.05 per cent) is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients one year of age or older and has annual sales of approximately $19 million, as measured by Symphony Health Solutions.
Perrigo's chairman and CEO Joseph C Papa stated, "This is another example of our Rx team's commitment to launching difficult to manufacture topicals, lotions and foams. We are excited to market this product and are dedicated to making quality healthcare more affordable for all consumers around the globe."
Perrigo Company, a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API).